(Date:12/2/2009)...ire/ -- S*BIO Pte Ltd today announced data present...t The American Society of Hematology 51st Annual M...ill be presented on the clinical results from the ...its safety, tolerability and pharmacokinetic/pharm...from 100 to 600 mg. These doses were administered ...
(Date:12/2/2009)...FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ...tical company focused on endocrine therapy and onc... Administration (FDA) has granted Fast Track desig...r compound, perifosine (KRX-0401), for the treatme...Biopharmaceuticals, Inc. ("Keryx") ( KERX), is AEt...
(Date:12/2/2009)...re/ -- According to the National Institute of Heal...d with diabetes already have some stage of diabeti...e retina caused by leaky blood vessels, is a major... one of the most feared diabetic complications. I...d diabetes for 10 years or more will experience so...
(Date:12/1/2009)...re/ -- Reportlinker.com announces that a new marke..., Chromium - Global Market Trends ,, ht...al-Market-Trends.html ,, Worldwide demand for ...l, while growth in aerospace and industrial gas tu...mium metal. Environmental constraints and rapid de...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4Reportlinker Adds Chromium - Global Market Trends 2Reportlinker Adds Chromium - Global Market Trends 3Reportlinker Adds Chromium - Global Market Trends 4Reportlinker Adds Chromium - Global Market Trends 5Reportlinker Adds Chromium - Global Market Trends 6Reportlinker Adds Chromium - Global Market Trends 7Reportlinker Adds Chromium - Global Market Trends 8Reportlinker Adds Chromium - Global Market Trends 9...SULTS, VANCOUVER, Oct. 25 /PRNewswire-FirstCall/ ...TSX: ANP), a global specialty pharmaceutical and,m... discussing its,financial results for the third qu...ember 1, 2007 at 11:00 AM ET, (8:00 AM Pacifi...information is as follows:, North America (to...
...AACR-NCI-EORTC International Conference on M...ancisco, QUEBEC CITY, Oct. 25 /PRNewswire-FirstCa...S), a global biopharmaceutical company focused on,... abstract outlining novel,data generated from thre...eted cytotoxic candidates at the AACR-NCI-EORTC In...
... Therapeutics,Inc. (OTC Bulletin Board: NILT.OB) w...lthcare Conference at 10:30 AM EST on Wednesday, N...Peter Strumph, Chief Executive Officer of Nile wil... clinical development programs,including data from...ead,compound, CD-NP, a novel chimeric peptide for ...
Other Biology Technology:Notice of Conference Call and Webcast 2AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment 2AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment 3AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment 4Nile Therapeutics to Present at the Rodman & Renshaw 9th Annual Healthcare Conference 2...ers at CSIRO Livestock Industries, Australian Anim...epartment of Primary Industries Victoria ?are inve...g the introduced fish. , Project leader Dr Mark C... in 1998*, caused mass mortalities in carp in the ...onesia. So far the virus does not appear to have r...
...ed immune response resulting from HIV infection ca...a, according to a new study appearing in the Oct. ... available online. , "Our study demonstrates that ...epresent, next to children and pregnant women, an ...n-Pierre Van geertruyden, MD, MSc, lead author of ...
...as 18 percent of adults who have no history of str...ke, according to results of a large national study...nternal Medicine, one of the JAMA/Archives journal...hout a history of stroke reveals that many have ha...ckground information in the article. One previous...
Other Biology News:Virus may control Australia's 2Malaria treatment efficacy compromised in certain HIV-positive patients 2Stroke symptoms common among general population 2...basic components and protocol required to develop ...tation of a specific protein in 100 l/well of cell...oating and Detection Antibodies, Recombinant Stand...B Substrate Solution (one-step) and Stop Solution....
...R) Competitor Assay Kits are ideal for studying or...pounds using fluorescence polarization (FP). The h...ransferase to the ligand binding domain of human p...ry, fluorescently tagged progesterone ligand, Fluo...
Organic Acid Analysis Standard, 6 vials from Bio-Rad
...ging Systems group announces the availability of K...eaturing high resolution cooled CCD camera technol...radiographic and chromogenic imaging capability. T...m lens provides spatial resolution of up to 10 mic...
Biology Products: